Navigation Links
NIH-funded study connects gene variant to response to asthma drugs
Date:9/26/2011

A genetic variant may explain why some people with asthma do not respond well to inhaled corticosteroids, the most widely prescribed medicine for long-term asthma control. Researchers found that asthma patients who have two copies of a specific gene variant responded only one-third as well to steroid inhalers as those with two copies of the regular gene.

This genome-wide association study, funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, analyzed data from over 1,000 people enrolled in five separate clinical trials that studied different steroid treatments for asthma.

The study was also funded by the National Human Genome Research Institute and the NIH Pharmacogenomics Research Network. The results will appear in the Sept. 26 online edition of the New England Journal of Medicine.

"This finding helps to explain the genetic basis for the long-standing observation that some people do not respond well to what is a common asthma treatment," said Susan Shurin, M.D., acting director of the NHLBI. "The study illustrates the importance of research examining the relationship between genetic makeup and response to therapy for asthma, and underscores the need for personalized treatment for those who have it."

Asthma is a complex inflammatory disease that affects over 22 million people in the United States and roughly 300 million people worldwide. Many factors can influence how severely the disease affects people and how well they respond to treatments. Poor response to inhaled corticosteroids (ICS) often runs in families, suggesting that genetics plays a role in how people respond to asthma treatments.

The study first conducted a genome-wide scan of the DNA of children enrolled in the Childhood Asthma Management Program and of their parents. The genomic scan uncovered a variant in a gene called GLCCI1 that appeared to be associated with poor ICS response. Study researchers then verified this association in 935 additional people with asthma, both children and adults, enrolled in four independent ICS studies. Most of the participants in these studies were white; the results may not be applicable to persons of other ethnicities.

In this study, people carrying two copies of the GLCCI1 variant were more than twice as likely to respond poorly to ICS treatment as participants with two copies of the regular GLCCI1 gene. Those who responded poorly had an average of one-third the level of lung improvement following inhaler treatment as did people with two regular copies of the gene.

About 1 in 6 study participants had two copies of the GLCCI1 variant, which is thought to work in conjunction with other genetic and environmental factors to affect response to ICS.

More studies will be needed to understand how GLCCI1 operates in the lungs and to explore whether it contributes to response in patients of other ethnic groups.


'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related biology news :

1. NIH-funded researchers discover genetic link to mesothelioma
2. NIH-funded research network to explore oil spill health effects
3. Rare gene glitch may hold clues for schizophrenia -- NIH-funded study
4. LSU researcher participates in NIH-funded study ushering in the age of personal genomics
5. NIH-funded scientists sequence genomes of lyme disease bacteria
6. NIH-funded studies aim to prevent, treat childhood obesity
7. NIH-funded researchers sequence exomes of 12 people
8. Study puts a new spin on ibuprofens actions
9. University of Arizona to study human-fire-climate interactions
10. Aquarium fishes are more aggressive in reduced environments, a new study finds
11. Harvard School of Public Health awarded $20 million CDC grant to study HIV prevention in Botswana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/21/2016)... 22, 2016 Unique technology ... for superior security   Xura, ... of secure digital communications services, today announced it is ... offer enterprise customers, particularly those in the Financial Services ... voice authentication within a mobile app, alongside, and in ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis ... cruciate ligament in her left knee. Lady’s owner Hannah sought the help of Dr ... veterinary surgeon, to repair her cruciate ligament and help with the pain of Lady’s ...
(Date:5/24/2016)...   MedyMatch Technology Ltd ., the data analytics healthcare ... support tools in the emergency room, announced today that it ... Technology Industries (IATI) BioMed Conference. The Conference ... National Life Sciences and Technology Week, and is being held ... Tel Aviv, Israel . Gene Saragnese ...
(Date:5/23/2016)... Antonio, Texas (PRWEB) , ... May 23, 2016 , ... The need for blood donations ... released this week by the South Texas Blood & Tissue Center, blood donations are on ... than 30 years, and they are down 21 percent in South Texas in the last ...
(Date:5/23/2016)... May 23, 2016 Oxitec CEO ... at 10:15 a.m. ET before the United States House ... engineered mosquitos can play in controlling the spread of the ... Zika virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... with a self-limiting gene. Trials in Brazil ...
Breaking Biology Technology: